Global HIV Vaccine Enterprise
The Global HIV Vaccine Enterprise promotes HIV vaccine development by sharing knowledge, fostering collaboration, prioritizing HIV vaccine R&D on the global health agenda, and supporting early-career African researchers and advocates through capacity-building initiatives. Established in 2003 and became a programme of the IAS in 2018, it aims to accelerate the development and access to an HIV vaccine, address scientific gaps, and foster collaboration among researchers, policymakers, and communities worldwide.
Industries
Nr. of Employees
small (1-50)
Products
Global HIV Vaccine Enterprise Strategic Plan 2022-2027
Strategic plan document outlining priorities, objectives and planned activities to advance HIV vaccine research and capacity building between 2022 and 2027.
Recorded webcasts and meeting reports
Archives of recorded webinars, roundtables and stakeholder meetings made available for reference and training.
Global HIV Vaccine Enterprise Strategic Plan 2022-2027
Strategic plan document outlining priorities, objectives and planned activities to advance HIV vaccine research and capacity building between 2022 and 2027.
Recorded webcasts and meeting reports
Archives of recorded webinars, roundtables and stakeholder meetings made available for reference and training.
Services
Multi-session online workshop series addressing current and future trial design approaches for ARV-based prevention, vaccines and monoclonal antibodies, including methodological presentations and panel discussions.
In-person academy providing training on HIV vaccine R&D topics including vaccine and trial design, laboratory and data analysis, scientific writing and networking opportunities for early- to mid-career African researchers.
Training programme for advocates and peer educators to build literacy in HIV vaccine research and skills for stakeholder engagement and community mobilisation.
Structured mentorship linking established scientific leaders with emerging investigators to support career development, research productivity and networking.
Two-year research fellowship opportunity for postdoctoral investigators to conduct HIV vaccine research with technical training and potential placements at international partner institutions.
In-person and virtual convenings that bring together researchers, funders, industry, regulators and community representatives to build consensus and set priorities for HIV vaccine R&D.
Multi-session online workshop series addressing current and future trial design approaches for ARV-based prevention, vaccines and monoclonal antibodies, including methodological presentations and panel discussions.
In-person academy providing training on HIV vaccine R&D topics including vaccine and trial design, laboratory and data analysis, scientific writing and networking opportunities for early- to mid-career African researchers.
Training programme for advocates and peer educators to build literacy in HIV vaccine research and skills for stakeholder engagement and community mobilisation.
Structured mentorship linking established scientific leaders with emerging investigators to support career development, research productivity and networking.
Two-year research fellowship opportunity for postdoctoral investigators to conduct HIV vaccine research with technical training and potential placements at international partner institutions.
In-person and virtual convenings that bring together researchers, funders, industry, regulators and community representatives to build consensus and set priorities for HIV vaccine R&D.
Expertise Areas
- Clinical trial management and design for prevention studies
- Experimental medicine and early-phase vaccine evaluation
- Statistical epidemiology and incidence inference methods
- Capacity building and mentorship in low- and middle-income settings
Key Technologies
- Viral vector vaccine platforms
- Nucleic acid (RNA/DNA) vaccine technologies
- Monoclonal antibodies and broadly neutralizing antibodies
- Passive antibody infusion approaches
News & Updates
Announcement of interim results from ViiV Healthcare showing that long-acting PrEP cabotegravir is 89% more effective than daily Truvada in women at increased risk of HIV, with implications for HIV prevention strategies.
Discontinuation of the Johnson & Johnson's Imbokodo HIV vaccine trial due to lack of efficacy, emphasizing the importance of continued investment and research in HIV vaccine development.
The discontinuation of the HVTN 702 trial in South Africa, based on futility, but with recognition of the importance of ongoing research and lessons learned for future vaccine development.
Announcement of interim results from ViiV Healthcare showing that long-acting PrEP cabotegravir is 89% more effective than daily Truvada in women at increased risk of HIV, with implications for HIV prevention strategies.
Discontinuation of the Johnson & Johnson's Imbokodo HIV vaccine trial due to lack of efficacy, emphasizing the importance of continued investment and research in HIV vaccine development.
The discontinuation of the HVTN 702 trial in South Africa, based on futility, but with recognition of the importance of ongoing research and lessons learned for future vaccine development.